A novel membrane antigen selectively expressed on terminally differentiated human B cells.
A novel membrane antigen selectively expressed on terminally differentiated human B cells.
复制标题
DOI：
10.1182/blood.v84.6.1922.bloodjournal8461922
复制
发表时间：
1994-09
期刊：
影响因子：
20.3
通讯作者：
Tetsuya Goto;Stephen J. Kennel;Masahiro Abe;Makoto Takishita;Masaaki Kosaka;Alan Solomon;Shiro Saito-S
中科院分区：
文献类型：
--
作者：
Tetsuya Goto;Stephen J. Kennel;Masahiro Abe;Makoto Takishita;Masaaki Kosaka;Alan Solomon;Shiro Saito-S
针对人浆细胞系开发了一种定义新型末端B细胞限制性抗原（称为HM 1.24）的单克隆抗体（MoAb）。被命名为抗HM 1.24的单克隆抗体与五种不同的人类骨髓瘤细胞系以及从多发性骨髓瘤或Waldenström巨球蛋白血症患者的骨髓或外周血中获得的单克隆肿瘤性浆细胞发生反应。HM 1.24抗原也可由成熟的Ig分泌型B细胞（浆细胞和淋巴浆细胞样细胞）表达，但正常个体或非浆细胞相关恶性肿瘤患者的外周血、骨髓、肝、脾、肾或心脏中所含的其他细胞不表达。抗HM 1.24单克隆抗体与人骨髓瘤RPMI 8226细胞结合的亲和常数为9.2 x 10（8）M-1，表明约84，000个位点/细胞。通过还原条件下的免疫沉淀试验，该单克隆抗体鉴定了分子量为29至33 kD的膜糖蛋白。我们的研究表明，HM 1.24相关蛋白代表了晚期B细胞成熟的特异性标志物，并可能作为多发性骨髓瘤和相关浆细胞恶液质免疫治疗的靶抗原。
A monoclonal antibody (MoAb) that defines a novel terminal B-cell-restricted antigen, termed HM1.24, was developed against a human plasma cell line. The MoAb, designated anti-HM1.24, reacted with five different human myeloma cell lines, as well as with monoclonal neoplastic plasma cells obtained from the bone marrow or peripheral blood of patients with multiple myeloma or Waldenström's macroglobulinemia. The HM1.24 antigen was also expressed by mature Ig-secreting B cells (plasma cells and lymphoplasmacytoid cells) but not by other cells contained in the peripheral blood, bone marrow, liver, spleen, kidney, or heart of normal individuals or patients with non-plasma-cell-related malignancies. The anti-HM1.24 MoAb bound to human myeloma RPMI 8226 cells with an affinity constant of 9.2 x 10(8) M-1, indicating approximately 84,000 sites/cell. By immunoprecipitation assay under reducing conditions, this MoAb identified a membrane glycoprotein that had a molecular weight of 29 to 33 kD. Our studies indicate that the HM1.24-related protein represents a specific marker of late-stage B-cell maturation and potentially serves as a target antigen for the immunotherapy of multiple myeloma and related plasma cell dyscrasias.